Intravenous Oxytocin for Post Operative Pain After Minimally Invasive Hysterectomy
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a randomized, double-blinded, placebo-controlled trial to compare the effectiveness of IV oxytocin infusion to placebo on peri-operative opioid consumption and reducing post-operative pain following a minimally invasive hysterectomy under general anesthesia.
Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:
• Ages 18-65 years old
• ASA category 1-3
• Scheduled to undergo minimally invasive hysterectomy
• No documented allergy to oxytocin
Locations
United States
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
Contact Information
Primary
John J. Kowalczyk, MD
jkowalczyk@bwh.harvard.edu
617-732-8220
Backup
Rusul I Al-Ani
rual-ani@bwh.harvard.edu
617-525-6483
Time Frame
Start Date: 2025-06-01
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 152
Treatments
Active_comparator: Medication
one group will receive Oxytocin infusion: 30 IU in 500 ml of 0.9% normal saline .
Placebo_comparator: Placebo
one group will receive 500 ml of 0.9% normal saline
Related Therapeutic Areas
Sponsors
Leads: Brigham and Women's Hospital